Bioinformatics analysis of targeted metabolomics - Uncovering old and new tales of diabetic mice under medication

Elisabeth Altmaier, Steven L. Ramsay, Armin Graber, Hans Werner Mewes, Klaus M. Weinberger, Karsten Suhre

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Metabolomics is a powerful tool for identifying both known and new disease-related perturbations in metabolic pathways. In preclinical drug testing, it has a high potential for early identification of drug off-target effects. Recent advances in high-precision high-throughput mass spectrometry have brought the metabolomic field to a point where quantitative, targeted, metabolomic measurements with ready-to-use kits allow for the automated in-house screening for hundreds of different metabolites in large sets of biological samples. Today, the field of metabolomics is, arguably, at a point where transcriptomics was about 5 yr ago. This being so, the field has a strong need for adapted bioinformatics tools and methods. In this paper we describe a systematic analysis of a targeted quantitative characterization of more than 800 metabolites in blood plasma samples from healthy and diabetic mice under rosiglitazone treatment. We show that known and new metabolic phenotypes of diabetes and medication can be recovered in a statistically objective manner. We find that concentrations of methylglutaryl carnitine are oppositely impacted by rosiglitazone treatment of both healthy and diabetic mice. Analyzing ratios between metabolite concentrations dramatically reduces the noise in the data set, allowing for the discovery of new potential biomarkers of diabetes, such as the N-hydroxyacyloylsphingosyl-phosphocholines SM(OH)28:0 and SM(OH)26:0. Using a hierarchical clustering technique on partial η2 values, we identify functionally related groups of metabolites, indicating a diabetes-related shift from lysophosphatidylcholine to phosphatidylcholine levels. The bioinformatics data analysis approach introduced here can be readily generalized to other drug testing scenarios and other medical disorders.

Original languageEnglish
Pages (from-to)3478-3489
Number of pages12
JournalEndocrinology
Volume149
Issue number7
DOIs
Publication statusPublished - Jul 2008
Externally publishedYes

Fingerprint

Metabolomics
rosiglitazone
Computational Biology
Pharmaceutical Preparations
Lysophosphatidylcholines
Phosphorylcholine
Carnitine
Metabolic Networks and Pathways
Phosphatidylcholines
Cluster Analysis
Mass Spectrometry
Biomarkers
Phenotype

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Bioinformatics analysis of targeted metabolomics - Uncovering old and new tales of diabetic mice under medication. / Altmaier, Elisabeth; Ramsay, Steven L.; Graber, Armin; Mewes, Hans Werner; Weinberger, Klaus M.; Suhre, Karsten.

In: Endocrinology, Vol. 149, No. 7, 07.2008, p. 3478-3489.

Research output: Contribution to journalArticle

Altmaier, Elisabeth ; Ramsay, Steven L. ; Graber, Armin ; Mewes, Hans Werner ; Weinberger, Klaus M. ; Suhre, Karsten. / Bioinformatics analysis of targeted metabolomics - Uncovering old and new tales of diabetic mice under medication. In: Endocrinology. 2008 ; Vol. 149, No. 7. pp. 3478-3489.
@article{8d6de384dff9416aaec71960188bae9f,
title = "Bioinformatics analysis of targeted metabolomics - Uncovering old and new tales of diabetic mice under medication",
abstract = "Metabolomics is a powerful tool for identifying both known and new disease-related perturbations in metabolic pathways. In preclinical drug testing, it has a high potential for early identification of drug off-target effects. Recent advances in high-precision high-throughput mass spectrometry have brought the metabolomic field to a point where quantitative, targeted, metabolomic measurements with ready-to-use kits allow for the automated in-house screening for hundreds of different metabolites in large sets of biological samples. Today, the field of metabolomics is, arguably, at a point where transcriptomics was about 5 yr ago. This being so, the field has a strong need for adapted bioinformatics tools and methods. In this paper we describe a systematic analysis of a targeted quantitative characterization of more than 800 metabolites in blood plasma samples from healthy and diabetic mice under rosiglitazone treatment. We show that known and new metabolic phenotypes of diabetes and medication can be recovered in a statistically objective manner. We find that concentrations of methylglutaryl carnitine are oppositely impacted by rosiglitazone treatment of both healthy and diabetic mice. Analyzing ratios between metabolite concentrations dramatically reduces the noise in the data set, allowing for the discovery of new potential biomarkers of diabetes, such as the N-hydroxyacyloylsphingosyl-phosphocholines SM(OH)28:0 and SM(OH)26:0. Using a hierarchical clustering technique on partial η2 values, we identify functionally related groups of metabolites, indicating a diabetes-related shift from lysophosphatidylcholine to phosphatidylcholine levels. The bioinformatics data analysis approach introduced here can be readily generalized to other drug testing scenarios and other medical disorders.",
author = "Elisabeth Altmaier and Ramsay, {Steven L.} and Armin Graber and Mewes, {Hans Werner} and Weinberger, {Klaus M.} and Karsten Suhre",
year = "2008",
month = "7",
doi = "10.1210/en.2007-1747",
language = "English",
volume = "149",
pages = "3478--3489",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Bioinformatics analysis of targeted metabolomics - Uncovering old and new tales of diabetic mice under medication

AU - Altmaier, Elisabeth

AU - Ramsay, Steven L.

AU - Graber, Armin

AU - Mewes, Hans Werner

AU - Weinberger, Klaus M.

AU - Suhre, Karsten

PY - 2008/7

Y1 - 2008/7

N2 - Metabolomics is a powerful tool for identifying both known and new disease-related perturbations in metabolic pathways. In preclinical drug testing, it has a high potential for early identification of drug off-target effects. Recent advances in high-precision high-throughput mass spectrometry have brought the metabolomic field to a point where quantitative, targeted, metabolomic measurements with ready-to-use kits allow for the automated in-house screening for hundreds of different metabolites in large sets of biological samples. Today, the field of metabolomics is, arguably, at a point where transcriptomics was about 5 yr ago. This being so, the field has a strong need for adapted bioinformatics tools and methods. In this paper we describe a systematic analysis of a targeted quantitative characterization of more than 800 metabolites in blood plasma samples from healthy and diabetic mice under rosiglitazone treatment. We show that known and new metabolic phenotypes of diabetes and medication can be recovered in a statistically objective manner. We find that concentrations of methylglutaryl carnitine are oppositely impacted by rosiglitazone treatment of both healthy and diabetic mice. Analyzing ratios between metabolite concentrations dramatically reduces the noise in the data set, allowing for the discovery of new potential biomarkers of diabetes, such as the N-hydroxyacyloylsphingosyl-phosphocholines SM(OH)28:0 and SM(OH)26:0. Using a hierarchical clustering technique on partial η2 values, we identify functionally related groups of metabolites, indicating a diabetes-related shift from lysophosphatidylcholine to phosphatidylcholine levels. The bioinformatics data analysis approach introduced here can be readily generalized to other drug testing scenarios and other medical disorders.

AB - Metabolomics is a powerful tool for identifying both known and new disease-related perturbations in metabolic pathways. In preclinical drug testing, it has a high potential for early identification of drug off-target effects. Recent advances in high-precision high-throughput mass spectrometry have brought the metabolomic field to a point where quantitative, targeted, metabolomic measurements with ready-to-use kits allow for the automated in-house screening for hundreds of different metabolites in large sets of biological samples. Today, the field of metabolomics is, arguably, at a point where transcriptomics was about 5 yr ago. This being so, the field has a strong need for adapted bioinformatics tools and methods. In this paper we describe a systematic analysis of a targeted quantitative characterization of more than 800 metabolites in blood plasma samples from healthy and diabetic mice under rosiglitazone treatment. We show that known and new metabolic phenotypes of diabetes and medication can be recovered in a statistically objective manner. We find that concentrations of methylglutaryl carnitine are oppositely impacted by rosiglitazone treatment of both healthy and diabetic mice. Analyzing ratios between metabolite concentrations dramatically reduces the noise in the data set, allowing for the discovery of new potential biomarkers of diabetes, such as the N-hydroxyacyloylsphingosyl-phosphocholines SM(OH)28:0 and SM(OH)26:0. Using a hierarchical clustering technique on partial η2 values, we identify functionally related groups of metabolites, indicating a diabetes-related shift from lysophosphatidylcholine to phosphatidylcholine levels. The bioinformatics data analysis approach introduced here can be readily generalized to other drug testing scenarios and other medical disorders.

UR - http://www.scopus.com/inward/record.url?scp=46349084465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46349084465&partnerID=8YFLogxK

U2 - 10.1210/en.2007-1747

DO - 10.1210/en.2007-1747

M3 - Article

C2 - 18372322

AN - SCOPUS:46349084465

VL - 149

SP - 3478

EP - 3489

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 7

ER -